{"id":1305,"date":"2016-09-29T17:34:45","date_gmt":"2016-09-29T12:04:45","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1305"},"modified":"2021-07-24T12:56:33","modified_gmt":"2021-07-24T07:26:33","slug":"business-cocktail-5","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5","title":{"rendered":"Bayer AG &#038; Evotec AG\u2019s deal; Plasticell and CellSpring AG\u2019s deal; Allergan Acquires Akarna;  Cambrex Acquires Pharmacore"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fea8f2c4eca\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fea8f2c4eca\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5\/#Bayer_AG_and_Evotec_AG_enter_a_multi-target_research_partnership_agreement\" >Bayer AG\u00a0and Evotec AG enter a multi-target research partnership agreement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5\/#Plasticell_and_CellSpring_AG_have_entered_into_an_agreement\" >Plasticell\u00a0and CellSpring AG have entered into an agreement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5\/#Allergan_Acquires_Akarna_Therapeutics\" >Allergan Acquires Akarna Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5\/#Cambrex_Acquires_Pharmacore\" >Cambrex Acquires Pharmacore<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Bayer_AG_and_Evotec_AG_enter_a_multi-target_research_partnership_agreement\"><\/span>Bayer AG\u00a0and Evotec AG enter a multi-target research partnership agreement<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec\u2019s Cure Nephron target pipeline. It will pay approximately $15.64m to Evotec during the contract period.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Plasticell_and_CellSpring_AG_have_entered_into_an_agreement\"><\/span>Plasticell\u00a0and CellSpring AG have entered into an agreement<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Plasticell and CellSpring have entered an agreement which aims to examine and validate the capability of osteogenic cell therapy and 3D cell cultures in drug screening. According to this agreement, the companies will be responsible\u00a0for developing 3D tissue models that accurately respond to the drug treatment. These 3D models are used in pharmaceutical industry in all stages of drug discovery, to evaluate the efficacy of lead compounds.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Allergan_Acquires_Akarna_Therapeutics\"><\/span>Allergan Acquires Akarna Therapeutics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Allergan\u00a0plans to develop novel treatments for non-alcoholic steatohepatitis (NASH) and other liver diseases through the acquisition of Akarna Therapeutics. The acquisition has been completed for a purchase consideration of $50m. Allergan will gain all rights to AKN-083 and a portfolio of additional development stage FXR compounds. Akarna Therapeutics will receive additional clinical, regulatory, developmental and commercialisation milestones of its drug candidate.<\/p>\n<h2 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Cambrex_Acquires_Pharmacore\"><\/span>Cambrex Acquires Pharmacore<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"text-align: justify;\">Cambrex Corporation, a manufacturer of small molecule innovator and generic active pharmaceutical ingredients (APIs), has acquired PharmaCore, which specializes in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approximately $25 million. The company is licensed with the US Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG\u00a0and Evotec AG enter a multi-target research partnership agreement Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement, Bayer will have all the rights to select clinical candidates and Evotec\u2019s Cure Nephron target pipeline. It will pay approximately $15.64m to Evotec during the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17349,70,107,2211,17348,17351,17346,17350,17347,678],"industry":[17225],"therapeutic_areas":[17239,17230,17278],"class_list":["post-1305","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-akarna-therapeutics","tag-allergan","tag-bayer","tag-cambrex","tag-cellspring","tag-dea","tag-evotec-ag","tag-pharmacore","tag-plasticell","tag-research","industry-pharmaceutical","therapeutic_areas-gastroenterology","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bayer &amp; Evotec\u2019s deal; Plasticell &amp; CellSpring\u2019s deal; Allergan Acquires<\/title>\n<meta name=\"description\" content=\"Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement,....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer &amp; Evotec\u2019s deal; Plasticell &amp; CellSpring\u2019s deal; Allergan Acquires\" \/>\n<meta property=\"og:description\" content=\"Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement,....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-09-29T12:04:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"301\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer & Evotec\u2019s deal; Plasticell & CellSpring\u2019s deal; Allergan Acquires","description":"Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement,....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5","og_locale":"en_US","og_type":"article","og_title":"Bayer & Evotec\u2019s deal; Plasticell & CellSpring\u2019s deal; Allergan Acquires","og_description":"Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement,....","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-09-29T12:04:45+00:00","article_modified_time":"2021-07-24T07:26:33+00:00","og_image":[{"width":960,"height":301,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5","name":"Bayer & Evotec\u2019s deal; Plasticell & CellSpring\u2019s deal; Allergan Acquires","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","datePublished":"2016-09-29T12:04:45+00:00","dateModified":"2021-07-24T07:26:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bayer and Evotec have agreed to develop novel treatments for chronic kidney disease in diabetic patients. According to the agreement,....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-5"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-5#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720.jpg","width":960,"height":301},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/09022515\/news-1074604_960_720-300x94.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Akarna Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cambrex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CellSpring<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DEA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Evotec AG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmacore<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plasticell<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">research<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Akarna Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Cambrex<\/span>","<span class=\"advgb-post-tax-term\">CellSpring<\/span>","<span class=\"advgb-post-tax-term\">DEA<\/span>","<span class=\"advgb-post-tax-term\">Evotec AG<\/span>","<span class=\"advgb-post-tax-term\">Pharmacore<\/span>","<span class=\"advgb-post-tax-term\">Plasticell<\/span>","<span class=\"advgb-post-tax-term\">research<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 10 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 29, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 29, 2016 5:34 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1305"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1305\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1173"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1305"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1305"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}